doi: 10.1161/01.CIR.0000059651.17045.77
(Circulation. 2003;107:1092.)
© 2003 American Heart Association, Inc.
Nanotechnology for Molecular Imaging and Targeted Therapy
From the Barnes-Jewish Hospital and Washington University Departments of Medicine, Biomedical Engineering, and Physics, St Louis, Mo.
Correspondence to Samuel A. Wickline, MD, Washington University School of Medicine Campus Box 8086, 660 South Euclid Ave, St Louis, MO 63110. E-mail: saw@wuphys.wustl.edu
Key Words: Editorials • contrast media • imaging
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
The recent emergence of "molecular imaging" as an integrated discipline in academic medical centers has set the stage for an evolutionary leap in diagnostic imaging and therapy.1 Molecular imaging is not a substitute for the traditional process of image formation and interpretation, but is intended to improve diagnostic accuracy and sensitivity by providing an in vivo analog of immunocytochemistry or in situ hybridization. It is less concerned with native image contrast or resolution, which are keys for depicting the effects of the disease on surrounding normal tissues, but rather, it seeks to enhance the conspicuity of microscopic pathologies by targeting the molecular components or processes that represent actual mechanisms of disease. Moreover, imaging will become crucial for in vivo characterization of the complex behaviors of disease in time and space that will tell us: where it is, how big it is, how fast it is developing, how many molecular processes are contributing simultaneously, what to treat it with, how it is responding to therapy, and how it is changing.
Elements fundamental to the growth of molecular imaging are exemplified in summary statements from the second Biomedical Imaging Symposium: Visualizing the Future of Biology and Medicine (Available at: http://www.becon1. nih.gov/symposium1999.htm), which convened at the National Institutes for Health (NIH) on June 25 and 26, 1999, and was cosponsored by the Biomedical Engineering Consortium (BECON), the Radiological Society of North America, and the American Institute of Medical and Biological Engineering. The goals of the Symposium were to: (1) "identify the most important
This article has been cited by other articles:
 |
|
 |
|
  R. P. Choudhury and E. A. Fisher Molecular Imaging in Atherosclerosis, Thrombosis, and Vascular Inflammation Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 983 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Sinusas, F. Bengel, M. Nahrendorf, F. H. Epstein, J. C. Wu, F. S. Villanueva, Z. A. Fayad, and R. J. Gropler Multimodality Cardiovascular Molecular Imaging, Part I Circ Cardiovasc Imaging, November 1, 2008; 1(3): 244 - 256. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Burtea, S. Laurent, O. Murariu, D. Rattat, G. Toubeau, A. Verbruggen, D. Vansthertem, L. Vander Elst, and R. N. Muller Molecular imaging of {alpha}v{beta}3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA Cardiovasc Res, April 1, 2008; 78(1): 148 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yang Nano- and Microparticle-based Imaging of Cardiovascular Interventions: Overview Radiology, May 1, 2007; 243(2): 340 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Elmaleh, A. J. Fischman, A. Tawakol, A. Zhu, T. M. Shoup, U. Hoffmann, A.-L. Brownell, and P. C. Zamecnik Detection of inflamed atherosclerotic lesions with diadenosine-5',5'''-P1,P4-tetraphosphate (Ap4A) and positron-emission tomography PNAS, October 24, 2006; 103(43): 15992 - 15996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Jaffer, P. Libby, and R. Weissleder Molecular and Cellular Imaging of Atherosclerosis: Emerging Applications J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1328 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Wickline, A. M. Neubauer, P. Winter, S. Caruthers, and G. Lanza Applications of Nanotechnology to Atherosclerosis, Thrombosis, and Vascular Biology Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 435 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Wolbarst and W. R. Hendee Evolving and Experimental Technologies in Medical Imaging Radiology, January 1, 2006; 238(1): 16 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. McNeil Nanotechnology for the biologist J. Leukoc. Biol., September 1, 2005; 78(3): 585 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fuster and R. J. Kim Frontiers in Cardiovascular Magnetic Resonance Circulation, July 5, 2005; 112(1): 135 - 144. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Abramowicz Ultrasonographic Contrast Media: Has the Time Come in Obstetrics and Gynecology? J. Ultrasound Med., April 1, 2005; 24(4): 517 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Moreno and V. Fuster The year in atherothrombosis J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2099 - 2110. [Full Text] [PDF]
|
|
|
|
|
|
J. V. Frangioni and R. J. Hajjar In Vivo Tracking of Stem Cells for Clinical Trials in Cardiovascular Disease Circulation, November 23, 2004; 110(21): 3378 - 3383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hood, J. R. Heath, M. E. Phelps, and B. Lin Systems Biology and New Technologies Enable Predictive and Preventative Medicine Science, October 22, 2004; 306(5696): 640 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Feinstein The powerful microbubble: from bench to bedside, from intravascular indicator to therapeutic delivery system, and beyond Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H450 - H457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Wickline Plaque characterization: surrogate markers or the real thing? J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1185 - 1187. [Full Text] [PDF]
|
|